gemcitabine — Full data
H1 2027
Completion of the trial is expected during the first half of 2027, after 86 events (i.e., patient deaths) have been observed.Source filing
RNXT biotech catalysts & pipeline
RENOVORX INC · Data as of 2026-09-08
Upcoming catalysts
intra-arterial gemcitabine — Full data
Late 2027
RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the very near term and final data readout in mid to late 2027.Source filing
intra-arterial gemcitabine delivered via RenovoCath (IAG) — Topline data
Late 2027
We continue to anticipate final data in mid to late 2027.Source filing